ARHGEF6

Across TCGA pan-cancer cohorts, ARHGEF6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGEF6 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ARHGEF6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where ARHGEF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	0.865	1.000	.033	18	view →
LUAD	DFS	Quartile	All	0.792	0.495	.019	7	view →
PDAC	DFS	Tertile	All	0.930	0.718	.016	5	view →
HNSC	DFS	Median	II,III,IV	0.897	0.993	.005	4	view →
GBM	DFS	Median	All	0.256	0.473	.014	3	view →
CCRCC	OS	Median	All	0.904	0.984	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGEF6–COAD (DFS)

Open the COAD breakdown →